
Contents

<i>Dedication</i>	<i>v</i>
<i>Preface</i>	<i>vii</i>
<i>Contributors</i>	<i>xiii</i>
PART I VACCINES: INTRODUCTION	
1 Clinical Impact of Vaccine Development <i>Puja H. Nambiar, Alejandro Delgado Daza, and Lawrence L. Livornese Jr</i>	3
2 Future Challenges for Vaccinologists <i>Sunil Thomas, Rima Dilbarova, and Rino Rappuoli</i>	41
3 Principles of Vaccination <i>Fred Zepp</i>	57
PART II TRENDS IN VACCINOLOGY	
4 Reverse Vaccinology: The Pathway from Genomes and Epitope Predictions to Tailored Recombinant Vaccines <i>Marcin Michalik, Bardya Djabanshiri, Jack C. Leo, and Dirk Linke</i>	87
5 Systems Vaccinology: Applications, Trends, and Perspectives <i>Johannes Sollner</i>	107
6 Proteomic Monitoring of B Cell Immunity <i>Radwa Ewaisha and Karen S. Anderson</i>	131
PART III VACCINES FOR HUMAN VIRAL DISEASES	
7 Development of Rabies Virus-Like Particles for Vaccine Applications: Production, Characterization, and Protection Studies <i>Diego Fontana, Marina Etcheverrigaray, Ricardo Kratje, and Claudio Prieto</i>	155
8 Analytic Vaccinology: Antibody-Driven Design of a Human Cytomegalovirus Subunit Vaccine <i>Anna Kabanova and Daniele Lilleri</i>	167
9 Generation of a Single-Cycle Replicable Rift Valley Fever Vaccine <i>Shin Murakami, Kaori Terasaki, and Shinji Makino</i>	187
10 Application of Droplet Digital PCR to Validate Rift Valley Fever Vaccines <i>Hoai J. Ly, Nandadeva Lokugamage, and Tetsuro Ikegami</i>	207
11 Methods to Evaluate Novel Hepatitis C Virus Vaccines <i>Gustaf Ahlén and Lars Frelin</i>	221
12 Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus <i>Gary Wong and Xiangguo Qiu</i>	245

13	Assessment of Functional Norovirus Antibody Responses by Blocking Assay in Mice	259
	<i>Maria Malm, Kirsi Tamminen, and Vesna Blazevic</i>	
14	Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant	269
	<i>Clifton McPherson, Richard Chubet, Kathy Holtz, Yoshikazu Honda-Okubo, Dale Barnard, Manon Cox, and Nikolai Petrovsky</i>	
15	Generation and Characterization of a Chimeric Tick-Borne Encephalitis Virus Attenuated Strain ChinTBEV	285
	<i>Hong-Jiang Wang, Xiao-Feng Li, and Cheng-Feng Qin</i>	
16	Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses	295
	<i>Michael A. Whitt, Thomas W. Geisbert, and Chad E. Mire</i>	
17	Reverse Genetics Approaches to Control Arenavirus	313
	<i>Luis Martínez-Sobrido, Benson Yee Hin Cheng, and Juan Carlos de la Torre</i>	
 PART IV VACCINES FOR HUMAN BACTERIAL DISEASES		
18	DNA Vaccines: A Strategy for Developing Novel Multivalent TB Vaccines	355
	<i>Jaemi S. Chu, Daniel O. Villarreal, and David B. Weiner</i>	
19	Overcoming Enterotoxigenic <i>Escherichia coli</i> Pathogen Diversity: Translational Molecular Approaches to Inform Vaccine Design	363
	<i>James M. Fleckenstein and David A. Rasko</i>	
20	Design and Purification of Subunit Vaccines for Prevention of <i>Clostridium difficile</i> Infection	385
	<i>Jerzy Karczewski, Jean-Luc Bodmer, James C. Cook, Rachel F. Xoconostle, Debbie D. Nahas, Joseph G. Joyce, Jon H. Heinrichs, and Susan Secore</i>	
21	The Design of a <i>Clostridium difficile</i> Carbohydrate-Based Vaccine	397
	<i>Mario A. Monteiro</i>	
22	Murine Models of Bacteremia and Surgical Wound Infection for the Evaluation of <i>Staphylococcus aureus</i> Vaccine Candidates	409
	<i>Linhui Wang and Jean C. Lee</i>	
23	Using MHC Molecules to Define a <i>Chlamydia</i> T Cell Vaccine	419
	<i>Karuna P. Karunakaran, Hong Yu, Leonard J. Foster, and Robert C. Brunham</i>	
24	An Approach to Identify and Characterize a Subunit Candidate <i>Shigella</i> Vaccine Antigen	433
	<i>Debasis Pore and Manoj K. Chakrabarti</i>	
25	Approach to the Discovery, Development, and Evaluation of a Novel <i>Neisseria meningitidis</i> Serogroup B Vaccine	445
	<i>Luke R. Green, Joseph Eiden, Li Hao, Tom Jones, John Perez, Lisa K. McNeil, Kathrin U. Jansen, and Annaliesa S. Anderson</i>	

26 Anti-Lyme Subunit Vaccines: Design and Development of Peptide-Based Vaccine Candidates. 471
Christina M. Small, Waithaka Mwangi, and Maria D. Esteve-Gassent

27 Assessment of Live Plague Vaccine Candidates. 487
Valentina A. Feodorova, Lidiya V. Sayapina, and Vladimir L. Motin

28 Highly Effective Soluble and Bacteriophage T4 Nanoparticle Plague Vaccines Against *Yersinia pestis* 499
Pan Tao, Marthandan Mahalingam, and Venigalla B. Rao

29 Development of Structure-Based Vaccines for Ehrlichiosis. 519
Sunil Thomas

PART V VACCINES FOR HUMAN FUNGAL DISEASES

30 Dendritic Cell-Based Vaccine Against Fungal Infection 537
Keigo Ueno, Makoto Urai, Kayo Ohkouchi, Yoshitsugu Miyazaki, and Yuki Kinjo

31 Flow Cytometric Analysis of Protective T-Cell Response Against Pulmonary *Coccidioides* Infection 551
Chiung-Yu Hung, Karen L. Wozniak, and Garry T. Cole

PART VI VACCINES FOR HUMAN PARASITIC DISEASES

32 High-Density Peptide Arrays for Malaria Vaccine Development. 569
Felix F. Loeffler, Johannes Pfeil, and Kirsten Heiss

33 Development and Assessment of Transgenic Rodent Parasites for the Preclinical Evaluation of Malaria Vaccines. 583
Diego A. Espinosa, Andrea J. Radtke, and Fidel Zavala

34 DNA Integration in *Leishmania* Genome: An Application for Vaccine Development and Drug Screening. 603
Tahereh Taberi, Negar Seyed, and Sima Rafati

35 Methods to Evaluate the Preclinical Safety and Immunogenicity of Genetically Modified Live-Attenuated *Leishmania* Parasite Vaccines 623
Sreenivas Gannavaram, Parna Bhattacharya, Ranadhir Dey, Nevien Ismail, Kumar Avishek, Poonam Salotra, Angamuthu Selvapandiyan, Abhay Satoskar, and Hira L. Nakhasi

36 The Use of Microwave-Assisted Solid-Phase Peptide Synthesis and Click Chemistry for the Synthesis of Vaccine Candidates Against Hookworm Infection 639
Abdullah A.H. Ahmad Fuaad, Mariusz Skwarczynski, and Istvan Toth

PART VII VACCINES FOR PRION DISEASES

37 Methods and Protocols for Developing Prion Vaccines 657
Kristen Marciniuk, Ryan Taschuk, and Scott Napper

PART VIII VACCINES FOR SUBSTANCE ABUSE AND TOXINS

- 38 Ricin-Holotoxin-Based Vaccines: Induction of Potent Ricin-Neutralizing Antibodies 683
Tamar Sabo, Chanoch Kronman, and Ohad Mazor
- 39 Synthesis of Hapten-Protein Conjugate Vaccines with Reproducible Hapten Densities 695
Oscar B. Torres, Carl R. Alving, and Gary R. Matyas

PART IX VACCINES FOR ALLERGY

- 40 Production of Rice Seed-Based Allergy Vaccines 713
Hidenori Takagi and Fumio Takaiwa
- 41 Allergy Vaccines Using a *Mycobacterium*-Secreted Antigen, Ag85B, and an IL-4 Antagonist 723
Yusuke Tsujimura and Yasuhiro Yasutomi
- 42 Development of House Dust Mite Vaccine 739
Qiuxiang Zhang and Chunqing Ai

PART X DEVELOPMENT OF TUMOR VACCINES

- 43 Cancer Vaccines: A Brief Overview 755
Sunil Thomas and George C. Prendergast
- 44 Dendritic Cell Vaccines 763
Rachel Lubong Sabado, Marcia Meseck, and Nina Bhardwaj
- 45 T-Cell Epitope Discovery for Therapeutic Cancer Vaccines 779
Sri Krishna and Karen S. Anderson
- 46 Peptide-Based Cancer Vaccine Strategies and Clinical Results 797
Erika Schneble, G. Travis Clifton, Diane F. Hale, and George E. Peoples
- 47 Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. 819
Kristen A. Batich, Adam M. Swartz, and John H. Sampson
- 48 Development of Antibody-Based Vaccines Targeting the Tumor Vasculature 839
Xiaodong Zhuang and Roy Bicknell

PART XI FORMULATION AND STABILITY OF VACCINES

- 49 Practical Approaches to Forced Degradation Studies of Vaccines 853
Manvi Hasija, Sepideh Aboutorabian, Nausheen Rahman, and Salvador F. Ausar

- Index* 867



<http://www.springer.com/978-1-4939-3385-3>

Vaccine Design

Methods and Protocols: Volume 1: Vaccines for Human
Diseases

Thomas, S. (Ed.)

2016, XIX, 873 p. 131 illus., 89 illus. in color., Hardcover

ISBN: 978-1-4939-3385-3

A product of Humana Press